Not sure how you can assume one large pharma would develop more indications all at once vs NEU licensing out to multiple. The assumption is a dangerous one given pharma delay developing indications all the time, just look at Acadia and FragileX. A single company still has finite human resources required to progress these, regardless of MC.
Share Price, page-8573
-
- There are more pages in this discussion • 3,808 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$12.94 |
Change
-0.200(1.52%) |
Mkt cap ! $1.653B | |||
| Open | High | Low | Value | Volume |
| $13.03 | $13.06 | $12.75 | $7.500M | 581.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2300 | $12.93 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.96 | 2086 | 1 |
View Market Depth
| Last trade - 16.10pm 11/10/2024 (20 minute delay) ? |
| NEU (ASX) Chart |